


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3715.17-1

In Re Application Of: PAULETTI, ET AL.



Serial No.
10/698,794

Filing Date
OCTOBER 31, 2003

Examiner
N/A

Group Art Unit
N/A

Title: THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO AND THROUGH COVERING EPITHELIA

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- the statement specified in 37 CFR 1.97(e);
- OR**
- the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
3715.17-1

In Re Application: PAULETTI, ET AL.

Serial No. 10/698,794	Filing Date OCTOBER 31, 2003	Examiner N/A	Group Art Unit N/A
--------------------------	---------------------------------	-----------------	-----------------------

THE THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO AND THROUGH COVERING



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 16-1331 as described below.
- Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F: _____)
_____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on FEBRUARY 5, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.
 Signature of Person Mailing Correspondence
HANA VERNY Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature


Dated: FEBRUARY 5, 2004

HANA VERNY (REG. NO. 30,518)
PETERS, VERNY, JONES & SCHMITT, L.L.P.
385 SHERMAN AVENUE, SUITE 6
PALO ALTO, CA 94306
TELEPHONE: (650)324-1677
FACSIMILE: (650)324-1678

cc:

FOR PTO-1449 (Modified)
**LIST OF PATENTS AND PUBLICATIONS FOR
 APPLICANTS INFORMATION DISCLOSURE
 STATEMENT**

(Use several sheets if necessary)



ATTY. DOCKET NO.

SERIAL NO.

3715.17-1

10/698,794

APPLICANT : PAULETTI, ET AL.

FILING DATE : OCTOBER 31, 2003

GROUP N/A

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
						YES	NO
			US				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

A	Antonios G. Mikos, et al., Preparation and Characterization of Poly(L-lactic acid) Foams, <i>Polymer</i> , 35/5:1068-1077 (1994).
B	Ch. Schugens, et al., Polylactide Macroporous Biodegradable Implants For Cell Transplantation. Preparation of Polylactide Foams by Liquid-Liquid Phase Separation, <i>Journal of Biomedical Materials Research</i> , 30:449-461 (1996).
C	P. Mura, et al., Evaluation of Transcutol as a Clonazepam Transdermal Permeation Enhancer From Hydrophilic Gel Formulations, <i>European Journal of Pharmaceutical Sciences</i> , 9:365-372 (2000).
D	Benjamin M. Wu, et al., Solid Free-Form Fabrication of Drug Delivery Devices, <i>Journal of Controlled Release</i> , 40:77-87 (1996).
E	Venkatram Prasad Shastri, et al., <i>In Situ</i> Pore Formation in a Polymer Matrix by Differential Polymer Degradation, <i>Biomaterials</i> , 24:3133-3137 (2003).
F	Venkatram Prasad Shastri, et al., Macroporous Polymer Foams by Hydrocarbon Templating, <i>PNAS</i> , 97/5 (1970-1975).
G	David J. Mooney, et al., Novel Approach to Fabricate Porous Sponges of Poly(D,L-lactic-co-glycolic acid) Without the Use of Organic Solvents, <i>Biomaterials</i> , 17/14:1417-1422 (1996).
H	J. Sohler, et al., A Novel Method to Obtain Protein Release From Porous Polymer Scaffolds: Emulsion Coating, <i>Journal of Controlled Release</i> , 87:57-68 (2003).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.